关于停药的相关内容

摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。
$ ?5 r3 `2 ?' L7 M, B$ h, h* c8 ], _    关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。
0 w& Z# [$ z8 A) U& E
2 T& J: M6 Z4 _作者：来自澳大利亚
. @" m' D" p; K9 p7 C! b. ?来源：Haematologica. 2011.8.9.
* E$ Y+ @$ H* p/ L4 d1 gDear Group,

, g: p2 C& S- O( I- h+ qSome of you are on Dasatinib (Sprycel) and we wish to give news on all CML
therapies. Here is a report from Australia on 3 patients who went off Sprycel
after stable molecular response (PCRU). 1 patient relapsed but 2/3 patients
remain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel
# a. O/ N: G( x  [3 Z. _does spike up the immune system so I hope more reports come out on this issue.

: K! e! W" f6 \7 n4 _; D; G: cThe remarkable news about Sprycel cessation is that all 3 patients had failed
) X  T6 G7 [7 }% bGleevec and Sprycel was their second TKI so they had resistant disease. This is
5 V* p+ M( B# r2 Ydifferent from the stopping Gleevec trial in France which only targets patients
who have done well on Gleevec.

Hopefully, the doctors will report on a larger study and long-term to see if the
response off Sprycel is sustained.
1 |( I- R; D9 X0 T) z
Best Wishes,
& ~5 r6 N  ~0 Z, a9 ~5 ~$ ~* rAnjana

# K* C* k3 K+ T

5 @6 ?: |' g% Y$ b2 w/ O0 d8 SHaematologica. 2011 Aug 9. [Epub ahead of print]
Durable complete molecular remission of chronic myeloid leukemia following
dasatinib cessation, despite adverse disease features.
5 w% s4 |9 M* l4 G* b' ~, {7 ?Ross DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.
Source
! |! B2 W$ V! }2 |Adelaide, Australia;

( g6 S$ n: q# d- x# [# Q4 {Abstract
4 O2 R8 _/ J( X4 ?: lPatients with chronic myeloid leukemia, treated with imatinib, who have a
/ @1 b5 Z' h& R3 e+ ldurable complete molecular response might remain in CMR after stopping
treatment. Previous reports of patients stopping treatment in complete molecular
. s# f- v; a9 O  j9 f1 {7 ]response have included only patients with a good response to imatinib. We
; J9 E% X% h. b( G7 N/ K: Wdescribe three patients with stable complete molecular response on dasatinib
8 s& N) J9 D9 i" L7 ?, ?treatment following imatinib failure. Two of the three patients remain in
" g/ b! E2 {0 ?% D/ Y! ]' \complete molecular response more than 12 months after stopping dasatinib. In
' c! p, |4 V6 ?6 _3 Dthese two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to
show that the leukemic clone remains detectable, as we have previously shown in
imatinib-treated patients. Dasatinib-associated immunological phenomena, such as
. U4 N5 H' F( Q0 W4 Q6 U* s3 C4 Q7 Jthe emergence of clonal T cell populations, were observed both in one patient
who relapsed and in one patient in remission. Our results suggest that the
5 g8 v) j+ U, X5 c2 V, Bcharacteristics of complete molecular response on dasatinib treatment may be
$ a8 _1 h5 e  O! dsimilar to that achieved with imatinib, at least in patients with adverse
disease features.

摘要：（STIM试验为法国的格列卫停药试验。）这个研究中，患者先是取得了CMR（融合基因转阴），然后停用格列卫，而后复发。15名复发患者在重新服药后又一次取得了CMR，他们同意再次停药。
    第一次CMR持续时间为31个月，然后患者停药，复发的中位时间为2.6个月，然后重新服用格列卫，中位时间5.3个月之后取得第二次CMR。保持第二次CMR中位时间19个月之后，患者同意再次停药，这次，15名患者中有5名在停药随访中位时间24个月后仍然保持了CMR，而10名患者在停药中位时间2月后第二次复发。
    请注意，这些患者都是在第一次CMR后停药然后又复发的患者。
6 f- n  Z. M+ ]* r3 U- i$ T
( v* j. F8 j( t4 H作者：来自法国STIM试验
来源：EHA 2011.6.会议摘要

很不错的文章，看来马老师家有考虑停药的想法了啊！祝福！

期盼易或特也能停药，但现在觉得是一个梦想！

这个非常有意义的研究。能吃下来停会再吃，再停，那是天大的好事